Phase II Multicenter Trial of the Austrian AGO With the Combination of Liposomal Doxorubicin (Myocet) and Carboplatin in Primary Advanced or Metastatic and Recurrent Endometrial Cancer.

Trial Profile

Phase II Multicenter Trial of the Austrian AGO With the Combination of Liposomal Doxorubicin (Myocet) and Carboplatin in Primary Advanced or Metastatic and Recurrent Endometrial Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Carboplatin (Primary) ; Doxorubicin liposomal (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jun 2013 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently' (last verified Feb 2011).
    • 09 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top